
Piramal Pharma Ltd is Rated Hold by MarketsMOJO
2026-11-09 10:10:04Piramal Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 28 October 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 November 2026, providing investors with the latest insights into its performance and outlook.
Read More
Broad-Based Technical Strength Lifts Piramal Pharma Ltd to 52-Week High of Rs 250.3
2026-11-09 09:51:26Trading above all major moving averages and buoyed by a string of positive technical signals, Piramal Pharma Ltd surged to a new 52-week high of Rs 250.3 on 09 Nov 2026, marking a significant milestone in its price momentum journey.
Read MorePiramal Pharma Gains 0.06%: 2 Key Factors Driving the Week
2026-11-07 12:00:08Key Events This Week Nov 2: New 52-week high at Rs.241.85 Nov 3: Technical momentum shifts signal bullish outlook Nov 6: Week closes at Rs.239.20 (+0.06%) Week OpenRs.239.05 Week CloseRs.239.20+0.06% Week High<div ...
Read MorePiramal Pharma Surges 25.26%: 5 Key Drivers Behind the Rally
2026-10-31 12:00:07Key Events This Week 26 Oct: Technical momentum shifts amid mixed signals 27 Oct: Mojo Grade upgraded from Strong Sell to Sell 28 Oct: New 52-week high at Rs.232.95 and strong quarterly turnaround 29 Oct: New 52-week high at Rs.239.4 and quality grade upgrade 30 Oct: New 52-week high at Rs.239.5 closes week on a strong note Week Open ...
Read More
Broad-Based Technical Strength Lifts Piramal Pharma Ltd to 52-Week High of Rs 239.5
2026-10-30 11:36:43Surging to an intraday peak of Rs 239.5 on 30 Oct 2026, Piramal Pharma Ltd has marked a significant milestone by reaching its highest price in the past 52 weeks. This advance comes amid a backdrop of sustained technical momentum and outperformance relative to its sector and the broader market.
Read More
Piramal Pharma Ltd Quality Grade Upgrade Signals Improving Fundamentals
2026-10-29 08:00:09Piramal Pharma Ltd has seen its quality grade upgraded from below average to average, reflecting notable improvements in key business fundamentals such as return on equity (ROE), return on capital employed (ROCE), and debt management. This upgrade accompanies a strong share price rally, underscoring renewed investor confidence amid a challenging pharmaceutical sector backdrop.
Read More
Broad-Based Technical Strength Lifts Piramal Pharma Ltd to 52-Week High of Rs 232.95
2026-10-28 12:37:22Surging to a fresh 52-week high of Rs 232.95 on 28 Oct 2026, Piramal Pharma Ltd has demonstrated remarkable price momentum, outperforming its sector by 15.65% in a single session and extending gains over three consecutive days for a total return of 21.09%. This rally unfolds amid a broader market environment where the Sensex trades near its 52-week low, underscoring the stock’s distinctive strength.
Read More
Piramal Pharma Ltd Reports Strong Quarterly Turnaround Amid Market Outperformance
2026-10-28 11:00:14Piramal Pharma Ltd has demonstrated a significant financial turnaround in the quarter ended September 2026, reversing previous negative trends with robust revenue growth and margin expansion. The company’s stock surged 13.25% on 28 Oct 2026, reflecting renewed investor confidence amid a broader market rally.
Read More
Piramal Pharma Ltd Sees Exceptional Volume Surge Amid Strong Price Gains
2026-10-28 10:00:16Piramal Pharma Ltd (PPLPHARMA) has emerged as one of the most actively traded stocks by volume on 28 Oct 2026, registering a remarkable 13.35% gain in a single day. The pharmaceutical and biotechnology company’s shares surged on robust trading volumes, signalling renewed investor interest and a potential shift in market sentiment despite a recent downgrade in its Mojo Grade.
Read MoreExercise Of Call Option To Acquire The Balance 26% Equity Stake In Yapan Bio Private Limited.
18-Nov-2026 | Source : BSEPlease find enclosed intimation of the exercise of call option to acquire the balance 26% equity stake in Yapan Bio Private Limited.
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
31-Oct-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for HDFC Mutual Fund
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30-Oct-2026 | Source : BSEPlease find enclosed details of Earning call Transcript held on 28th October 2026.
Corporate Actions
No Upcoming Board Meetings
Piramal Pharma Ltd has declared 1% dividend, ex-date: 16 Jul 25
No Splits history available
No Bonus history available
Piramal Pharma Ltd has announced 5:46 rights issue, ex-date: 02 Aug 23